• Inhibrx Biosciences recently reported updated interim Phase 1/2 data showing that ozekibart (INBRX-109) plus FOLFIRI achieved a 20% objective response rate, 87% disease control rate, and manageable safety in heavily pretreated patients with unresectable colorectal cancer, while also advancing a Biologics License Application for ozekibart in conventional chondrosarcoma.
• These data position ozekibart as a potential first-in-class DR5 agonist with activity across multiple hard-to-treat solid tumors and ongoing FDA interactions around registrational and accelerated pathways.
• With the shares up over the past week, we'll examine how ozekibart’s colorectal cancer efficacy update reshapes Inhibrx Biosciences’ investment narrative.

Find 55 companies with promising cash flow potential yet trading below their fair value.

What Is Inhibrx Biosciences' Investment Narrative?

To own Inhibrx Biosciences you really have to buy into ozekibart as a platform, not just a single-asset bet in a niche sarcoma. The latest colorectal cancer update, with a 20% response rate and high disease control in heavily pretreated patients, reinforces the idea that this DR5 agonist could matter in multiple hard-to-treat tumors and gives more weight to upcoming FDA interactions around both fourth-line CRC and first-line trial design. That meaningfully sharpens the near-term catalyst map alongside the already filed BLA in chondrosarcoma, while also helping explain the very large share price move. At the same time, the story is still early: Inhibrx has minimal revenue, sizeable continuing losses, a relatively new leadership team and an expensive balance sheet, so the execution bar on trial design, regulatory discussions and eventual commercialization remains high.

However, the combination of minimal revenue and ongoing losses is something investors should pay close attention to. Insights from our recent valuation report point to the potential overvaluation of Inhibrx Biosciences shares in the market.

Exploring Other Perspectives

Only one fair value estimate from the Simply Wall St Community pegs Inhibrx at US$300 per share, hinting at strong optimism. Set that against the company’s lack of meaningful revenue and continuing losses, and it becomes clear you will want to look at several viewpoints before forming your own expectations for how the story might evolve.

Explore another fair value estimate on Inhibrx Biosciences - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Inhibrx Biosciences research is our analysis highlighting 2 important warning signs that could impact your investment decision.
• Our free Inhibrx Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Inhibrx Biosciences' overall financial health at a glance.

Want Some Alternatives?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.